RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. #lymphoma #lymsm https://t.co/HlZDVQ35pD
RT @UoS_Medicine: The @SouthamptonCTU RiVa trial (RiVa – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell mal…
The @SouthamptonCTU RiVa trial (RiVa – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomised controlled trial) has had a protocol paper published in Trials. Read more: https://t.co/Dyi
RT @SouthamptonCTU: Protocol published for RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignanci…
Protocol published for RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies https://t.co/pUI15RIpfp @UoS_Medicine @CRUKSouthampton @CCI_UoS @uoscares @UoS_WISHlab https://t.co/KBevvO3oC1
New from #CR_UK https://t.co/N1LW2PCOnn RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial. #lymphoma #lymsm https://t.co/HlZDVQ35pD